Brokerages expect Innophos Holdings, Inc. (NASDAQ:IPHS) to report $0.59 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Innophos’ earnings. Innophos posted earnings of $0.57 per share during the same quarter last year, which indicates a positive year over year growth rate of 3.5%. The firm is scheduled to report its next earnings report on Tuesday, August 7th.
On average, analysts expect that Innophos will report full-year earnings of $2.70 per share for the current fiscal year. For the next year, analysts anticipate that the company will report earnings of $3.00 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Innophos.
Innophos (NASDAQ:IPHS) last released its earnings results on Tuesday, May 1st. The specialty chemicals company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.06. The company had revenue of $205.00 million for the quarter, compared to analyst estimates of $196.91 million. Innophos had a net margin of 2.95% and a return on equity of 14.26%. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.59 EPS.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Innophos by 1.4% during the 4th quarter. BlackRock Inc. now owns 2,492,051 shares of the specialty chemicals company’s stock worth $116,453,000 after acquiring an additional 34,169 shares during the period. Segall Bryant & Hamill LLC raised its holdings in Innophos by 10.8% in the first quarter. Segall Bryant & Hamill LLC now owns 1,090,307 shares of the specialty chemicals company’s stock valued at $43,841,000 after buying an additional 105,965 shares during the period. Dimensional Fund Advisors LP raised its holdings in Innophos by 1.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,012,438 shares of the specialty chemicals company’s stock valued at $40,710,000 after buying an additional 17,808 shares during the period. Frontier Capital Management Co. LLC raised its holdings in Innophos by 4.3% in the first quarter. Frontier Capital Management Co. LLC now owns 859,312 shares of the specialty chemicals company’s stock valued at $34,553,000 after buying an additional 35,685 shares during the period. Finally, American Century Companies Inc. raised its holdings in Innophos by 5.1% in the first quarter. American Century Companies Inc. now owns 811,618 shares of the specialty chemicals company’s stock valued at $32,635,000 after buying an additional 39,151 shares during the period. Institutional investors and hedge funds own 94.72% of the company’s stock.
Innophos opened at $47.54 on Friday, MarketBeat Ratings reports. The stock has a market capitalization of $933.45 million, a price-to-earnings ratio of 19.33 and a beta of 0.78. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.70 and a current ratio of 3.22. Innophos has a 12-month low of $38.66 and a 12-month high of $51.34.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 5th. Stockholders of record on Friday, May 18th will be issued a dividend of $0.48 per share. The ex-dividend date is Thursday, May 17th. This represents a $1.92 annualized dividend and a dividend yield of 4.04%. Innophos’s payout ratio is currently 78.05%.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.